Navigation Links
Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
Date:3/10/2009

RICHMOND, Va., March 10 /PRNewswire-FirstCall/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOB) and biopharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has issued a statement on its website in regards to the agency's position on allowing patients with Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) access to IPLEX(TM) under an Investigational New Drug (IND) application. The statement can be accessed at: http://www.fda.gov/cder/drug/infopage/mecasermin_rinfabate/FDA_statement.htm.

About Insmed

Insmed Inc. is a biopharmaceutical company with unique protein process development and manufacturing experience and a proprietary protein platform aimed at niche markets with unmet medical needs. For more information, please visit www.insmed.com.

Forward-Looking Statements

This release contains forward-looking statements which are made pursuant to provisions of Section 21E of the Securities Exchange Act of 1934. Investors are cautioned that such statements in this release, including statements relating to planned clinical study design, regulatory and business strategies, plans and objectives of management and growth opportunities for existing or proposed products, constitute forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the forward-looking statements. The risks and uncertainties include, without limitation, risks that closing conditions under our agreement with Merck & Co., Inc. may not be met, product candidates may fail in the clinic or may not be successfully marketed or manufactured, we may lack financial resources to complete development of product candidates, the FDA may interpret the results of studies differently than us, competing products may be more successful, demand for new pharmaceutical products may decrease, the biopharmaceutical industry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for MMD may not actually match up with our external assessment, our common stock could be delisted from the Nasdaq Capital Market and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:
    Brian Ritchie - FD
    212-850-5683
    brian.ritchie@fd.com

    Media Contact:
    Irma Gomez-Dib - FD
    212-850-5761
    irma.gomez-dib@fd.com


'/>"/>
SOURCE Insmed Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Insmed to Present at the IBC 5th Annual Global Follow-On Biologics Conference
2. Insmed to Present at Upcoming Healthcare Conferences
3. Insmed Gains Royalty-Free Worldwide Rights for IPLEX(TM) in Connection with Potential Expanded Access ALS Programs
4. Insmed and Premacure Announce European Orphan Designation for IPLEX(TM) in Retinopathy of Prematurity in Infants
5. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
6. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
7. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
8. HEI, Inc. Announces Sale of RFID Division Assets
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
11. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... Georgia (PRWEB) , ... May 26, 2016 , ... ... certificate in intellectual property (IP) to its specialty academic programs. , Answering to ... the college’s existing certificate programs in health law, and environmental and land use ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... a significant negative impact on long-term patient survival, reports a team of UPMC ... online this week in the Journal of Thoracic and Cardiovascular Surgery, provide critical ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. James Maisel will present ... Island Chapter on June 4, 2016, 1:30-3:30 pm at the Farmingdale Public Library. ... Retina Group of New York , is a Board Certified ophthalmologist who completed ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... supply chain solutions, today announced the organization has earned its ISO 13485 certification, ... and is compliant with all rules and policies associated with ISO quality standard ...
(Date:5/26/2016)... ... 26, 2016 , ... Nike Yoga Camps at East West ... arts & crafts, discussions, and games all geared towards enhancing your child’s physical ... backgrounds in kids’ yoga, collegiate sport yoga instruction, and global yoga training. Nike ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... YORK , May 25, 2016 ... Market Size, Share, Development, Growth and Demand Forecast to ... Syringe, Insulin Pump and Others)" published by P&S Market ... at $9,998.3 million in 2015, and it is expected ... Based on type, the insulin pump segment is expected ...
(Date:5/25/2016)... Inivata, a global clinical ... tumour DNA (ctDNA) analysis to improve personalised healthcare ... Clive Morris as Chief Medical Officer. ... development programme, scientific collaborations, and through to commercialisation ... in clinical outcomes for patients. Clive ...
(Date:5/24/2016)...   , Study met ... and superiority in , Excellent plus ... of the ascending colon   , ... B.V. today announced new positive data from the phase III MORA ... standard 2 litre PEG with ascorbate. The study met both primary ...
Breaking Medicine Technology: